NexImmune Inc is a biotechnology business based in the US. NexImmune Inc shares (NEXI) are listed on the NASDAQ and all prices are listed in US Dollars. NexImmune Inc employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.70 |
|---|---|
| 52-week range | $1.25 - $21.00 |
| 50-day moving average | $2.87 |
| 200-day moving average | $4.60 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-24.11 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.7 from 2024-07-22
| 1 week (2024-07-17) | -24.44% |
|---|---|
| 1 month (2024-06-24) | -39.29% |
| 3 months (2024-04-24) | -47.85% |
| 6 months (2024-01-24) | -67.18% |
| 1 year (2023-07-24) | 470.47% |
|---|---|
| 2 years (2022-07-22) | 23.19% |
| 3 years (2021-07-23) | 10.67 |
| 5 years (2019-07-20) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -69.71% |
| Return on equity TTM | -196.48% |
| Profit margin | 0% |
| Book value | $2.00 |
| Market Capitalization | $2.6 million |
TTM: trailing 12 months
We're not expecting NexImmune Inc to pay a dividend over the next 12 months.
NexImmune Inc's shares were split on a 1:25 basis on 18 October 2023. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NexImmune Inc shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for NexImmune Inc shares which in turn could have impacted NexImmune Inc's share price.
Over the last 12 months, NexImmune Inc's shares have ranged in value from as little as $1.25 up to $21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NexImmune Inc's is 1.937. This would suggest that NexImmune Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put NexImmune Inc's beta into context you can compare it against those of similar companies.
NexImmune, Inc. , a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.